Cargando…

In Vitro Activity of Ceftolozane-Tazobactam and Other Antibiotics against Pseudomonas aeruginosa Infection-Isolates from an Academic Medical Center in Thailand

(1) Background: Resistant Pseudomonas aeruginosa (PA) infections have limited treatment options. Data on the activity of ceftolozane-tazobactam (C-T) against PA in Thailand are limited. Objectives: The objective of this study was to identify the in vitro activity of C-T against general and resistant...

Descripción completa

Detalles Bibliográficos
Autores principales: Tantisiriwat, Woraphot, Buppanharun, Jirawat, Ekpanyaskul, Chatchai, Onruang, Kwanchai, Yungyuen, Thitiya, Kiratisin, Pattarachai, Santiwatanakul, Somchai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219754/
https://www.ncbi.nlm.nih.gov/pubmed/35740139
http://dx.doi.org/10.3390/antibiotics11060732
_version_ 1784732196188192768
author Tantisiriwat, Woraphot
Buppanharun, Jirawat
Ekpanyaskul, Chatchai
Onruang, Kwanchai
Yungyuen, Thitiya
Kiratisin, Pattarachai
Santiwatanakul, Somchai
author_facet Tantisiriwat, Woraphot
Buppanharun, Jirawat
Ekpanyaskul, Chatchai
Onruang, Kwanchai
Yungyuen, Thitiya
Kiratisin, Pattarachai
Santiwatanakul, Somchai
author_sort Tantisiriwat, Woraphot
collection PubMed
description (1) Background: Resistant Pseudomonas aeruginosa (PA) infections have limited treatment options. Data on the activity of ceftolozane-tazobactam (C-T) against PA in Thailand are limited. Objectives: The objective of this study was to identify the in vitro activity of C-T against general and resistant PA isolates from patients with real clinical infections from the HRH Princess Maha Chakri Sirindhorn Medical Center (MSMC) compared to other antibiotics and to study the resistant molecular patterns of those PA strains which were resistant to C-T. (2) Materials and Methods: This was an in vitro susceptibility study of 100 PA isolates plus an additional seven resistant PA isolates collected from MSMC patients. All PA isolates were tested with susceptibility broth (Sensititre™) and C-T minimal inhibitory concentration (MIC) test strips (Liofilchem, Roseto degli, Abruzzi, Italy). The C-T-resistant PA isolates were analyzed for six β-lactamase genes (bla(CTX-M), bla(NDM), bla(IMP), bla(VIM), bla(OXA-23) and bla(OXA-48)) and the mcr-1 gene. (3) Results: A total of 100 PA isolates were collected between January 2020 and January 2021 and between February 2021 and September 2021 for the additional 7 resistant isolates. There were 18 resistant PA isolates (6 MDR, 11 XDR and 1 pan-drug resistant isolate). The overall susceptibility of the initial 100 PA isolates and the 18 resistant PA isolates was 94% and 44.5%, respectively, for C-T. The C-T susceptibility rates for isolates non-susceptible to ceftazidime, piperacillin-tazobactam, carbapenems and antipseudomonal β-lactams were 65.5%, 69.7%, 50% and 44.5%, respectively. Among the 10 isolates which were resistant to C-T, there were only 3 isolates found to have the resistant gene, which included 1 for bla(IMP), 1 for bla(VIM) and 1 for bla(NDM). (4) Conclusions: Although C-T was the best susceptibility antibiotic overall for PA isolates and MDR PA isolates at the MSMC, most of the XDR PA isolates and the PDR PA isolate were not susceptible to C-T. The mechanisms for C-T resistance involved multiple factors including the presence of bla(IMP), bla(VIM) and bla(NDM).
format Online
Article
Text
id pubmed-9219754
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92197542022-06-24 In Vitro Activity of Ceftolozane-Tazobactam and Other Antibiotics against Pseudomonas aeruginosa Infection-Isolates from an Academic Medical Center in Thailand Tantisiriwat, Woraphot Buppanharun, Jirawat Ekpanyaskul, Chatchai Onruang, Kwanchai Yungyuen, Thitiya Kiratisin, Pattarachai Santiwatanakul, Somchai Antibiotics (Basel) Article (1) Background: Resistant Pseudomonas aeruginosa (PA) infections have limited treatment options. Data on the activity of ceftolozane-tazobactam (C-T) against PA in Thailand are limited. Objectives: The objective of this study was to identify the in vitro activity of C-T against general and resistant PA isolates from patients with real clinical infections from the HRH Princess Maha Chakri Sirindhorn Medical Center (MSMC) compared to other antibiotics and to study the resistant molecular patterns of those PA strains which were resistant to C-T. (2) Materials and Methods: This was an in vitro susceptibility study of 100 PA isolates plus an additional seven resistant PA isolates collected from MSMC patients. All PA isolates were tested with susceptibility broth (Sensititre™) and C-T minimal inhibitory concentration (MIC) test strips (Liofilchem, Roseto degli, Abruzzi, Italy). The C-T-resistant PA isolates were analyzed for six β-lactamase genes (bla(CTX-M), bla(NDM), bla(IMP), bla(VIM), bla(OXA-23) and bla(OXA-48)) and the mcr-1 gene. (3) Results: A total of 100 PA isolates were collected between January 2020 and January 2021 and between February 2021 and September 2021 for the additional 7 resistant isolates. There were 18 resistant PA isolates (6 MDR, 11 XDR and 1 pan-drug resistant isolate). The overall susceptibility of the initial 100 PA isolates and the 18 resistant PA isolates was 94% and 44.5%, respectively, for C-T. The C-T susceptibility rates for isolates non-susceptible to ceftazidime, piperacillin-tazobactam, carbapenems and antipseudomonal β-lactams were 65.5%, 69.7%, 50% and 44.5%, respectively. Among the 10 isolates which were resistant to C-T, there were only 3 isolates found to have the resistant gene, which included 1 for bla(IMP), 1 for bla(VIM) and 1 for bla(NDM). (4) Conclusions: Although C-T was the best susceptibility antibiotic overall for PA isolates and MDR PA isolates at the MSMC, most of the XDR PA isolates and the PDR PA isolate were not susceptible to C-T. The mechanisms for C-T resistance involved multiple factors including the presence of bla(IMP), bla(VIM) and bla(NDM). MDPI 2022-05-30 /pmc/articles/PMC9219754/ /pubmed/35740139 http://dx.doi.org/10.3390/antibiotics11060732 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tantisiriwat, Woraphot
Buppanharun, Jirawat
Ekpanyaskul, Chatchai
Onruang, Kwanchai
Yungyuen, Thitiya
Kiratisin, Pattarachai
Santiwatanakul, Somchai
In Vitro Activity of Ceftolozane-Tazobactam and Other Antibiotics against Pseudomonas aeruginosa Infection-Isolates from an Academic Medical Center in Thailand
title In Vitro Activity of Ceftolozane-Tazobactam and Other Antibiotics against Pseudomonas aeruginosa Infection-Isolates from an Academic Medical Center in Thailand
title_full In Vitro Activity of Ceftolozane-Tazobactam and Other Antibiotics against Pseudomonas aeruginosa Infection-Isolates from an Academic Medical Center in Thailand
title_fullStr In Vitro Activity of Ceftolozane-Tazobactam and Other Antibiotics against Pseudomonas aeruginosa Infection-Isolates from an Academic Medical Center in Thailand
title_full_unstemmed In Vitro Activity of Ceftolozane-Tazobactam and Other Antibiotics against Pseudomonas aeruginosa Infection-Isolates from an Academic Medical Center in Thailand
title_short In Vitro Activity of Ceftolozane-Tazobactam and Other Antibiotics against Pseudomonas aeruginosa Infection-Isolates from an Academic Medical Center in Thailand
title_sort in vitro activity of ceftolozane-tazobactam and other antibiotics against pseudomonas aeruginosa infection-isolates from an academic medical center in thailand
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219754/
https://www.ncbi.nlm.nih.gov/pubmed/35740139
http://dx.doi.org/10.3390/antibiotics11060732
work_keys_str_mv AT tantisiriwatworaphot invitroactivityofceftolozanetazobactamandotherantibioticsagainstpseudomonasaeruginosainfectionisolatesfromanacademicmedicalcenterinthailand
AT buppanharunjirawat invitroactivityofceftolozanetazobactamandotherantibioticsagainstpseudomonasaeruginosainfectionisolatesfromanacademicmedicalcenterinthailand
AT ekpanyaskulchatchai invitroactivityofceftolozanetazobactamandotherantibioticsagainstpseudomonasaeruginosainfectionisolatesfromanacademicmedicalcenterinthailand
AT onruangkwanchai invitroactivityofceftolozanetazobactamandotherantibioticsagainstpseudomonasaeruginosainfectionisolatesfromanacademicmedicalcenterinthailand
AT yungyuenthitiya invitroactivityofceftolozanetazobactamandotherantibioticsagainstpseudomonasaeruginosainfectionisolatesfromanacademicmedicalcenterinthailand
AT kiratisinpattarachai invitroactivityofceftolozanetazobactamandotherantibioticsagainstpseudomonasaeruginosainfectionisolatesfromanacademicmedicalcenterinthailand
AT santiwatanakulsomchai invitroactivityofceftolozanetazobactamandotherantibioticsagainstpseudomonasaeruginosainfectionisolatesfromanacademicmedicalcenterinthailand